Autologous blood donation by Goodnough, Lawrence T
S49 EPO = erythropoietin; PAD = preoperative autologous blood donation; RBC = red blood cell.
Available online http://ccforum.com/content/8/S2/S49
Introduction
Preoperative autologous blood donation (PAD) was developed
and promoted [1] in the surgical arena in response to medical
and legal pressures to minimize exposure to allogeneic blood.
The role of PAD in surgery continues to evolve, based on
improved blood safety, increased blood costs, and emerging
pharmacologic alternatives to blood transfusion [2]. PAD
became accepted as a standard practice in certain elective
surgical settings, such as total joint replacement surgery, so
that by 1992 more than 6% of the blood transfused in the USA
was autologous [3]. Subsequently, improvements in blood
safety have led to a decline not only in the use of PAD (Table 1)
but also in interest in exploring other autologous blood procure-
ment strategies. Nevertheless, public perception of blood
safety and the reluctance to accept allogeneic blood transfu-
sion in the elective transfusion setting [4], along with emerging
blood inventory shortages, render the application of autologous
blood procurement strategies a subject of ongoing debate.
Efficacy
Patients undergoing PAD may donate a unit (450 ± 45 ml, or
up to 10.5 ml/kg body weight) of blood as often as twice
weekly, until 72 hours before surgery. Under routine conditions,
patients usually donate once weekly. Oral iron supplements are
routinely prescribed. This iatrogenic blood loss is accompanied
by a response in endogenous erythropoietin (EPO) levels that,
although increased significantly over basal levels, remain within
the normal range. The erythropoietic response that occurs
under these conditions is therefore modest [5]. A summary of
prospective, controlled trials of patients undergoing such blood
loss via autologous phlebotomy is presented in Table 2 [6–11],
along with calculated estimates of red blood cell (RBC) volume
expansion (erythropoiesis in excess of basal rates). With
routine PAD, erythropoiesis of 220–351 ml (11–19% RBC
expansion) [6,7], or the equivalent of 1–1.75 blood units,
occurs in excess of basal erythropoiesis, which indicates the
efficacy of this blood conservation practice.
For patients subjected to more aggressive phlebotomy (up to
2 units weekly), the endogenous EPO response is more sub-
stantial [8–11]. In one clinical trial [9], a linear-logarithmic rela-
tionship was demonstrated between change in hemoglobin
level and the endogenous EPO response [12]. EPO-mediated
erythropoiesis in this setting is 397–568 ml (19–26% RBC
expansion) [8–11], or the equivalent of 2–3 blood units. When
recombinant human EPO therapy is administered during PAD,
the equivalent of 5 blood units is generated [10,13].
Patient selection
Preoperative autologous collections are most beneficial to
those patients who are undergoing procedures with substan-
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Abstract
Although preoperative autologous blood donation is employed in elective surgery, this is declining
because of the increasingly safe allogeneic blood supply. However, it continues to be used because of
the public’s perception of allogeneic blood risks and increasing blood shortages. Patients may donate
a unit of blood (450 ± 45 ml) as often as twice weekly, up to 72 hours before surgery. Preoperative
autologous blood is most beneficial in procedures that cause significant blood loss. It has been
determined that preoperative autologous blood donation is poorly cost-effective; the use of this
procedure must be based on evidence that it is safe and of value for the patient.
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ment, vascular surgery, cardiac or thoracic surgery, and radical
prostatectomy. Autologous blood is unnecessary for proce-
dures that seldom require transfusion, such as transurethral
resection of the prostate, cholecystectomy, herniorrhaphy,
vaginal hysterectomy, and uncomplicated obstetric delivery
[14]. A hospital’s maximal surgical blood order schedule for
blood cross-match can provide estimates of transfusion rates
for specific procedures; the generally accepted cutoff at
which transfusion is ‘unlikely’ and autologous blood procure-
ment should not be recommended is 10% [15].
Collection of units should be scheduled as far in advance of
surgery as possible for liquid blood storage (up to 42 days),
to allow compensatory erythropoiesis [5] to correct the
induced anemia. If the erythropoietic response to autologous
blood phlebotomy is not able to maintain the patient’s level of
hematocrit during the donation interval, then the pre-deposit
of autologous blood may actually be harmful. A study of
patients undergoing hysterectomy [16] found that PAD
resulted in perioperative anemia and an increased likelihood
of any blood transfusion.
Even though national trends indicate a decline in PAD for all
surgical patients in the USA, this practice remains a standard
of care for patients undergoing total joint replacement
surgery. A multicenter retrospective audit of 9482 patients
Table 1
Collection and transfusion of autologous blood in the USA
Year
Source 1980 1986 1989 1992 1994 1997 1999 2001
Collected
Autologous 28 206 655 1117 1013 611 651 619
Percentage of total 0.25% 1.5% 4.8% 8.5% 7.8% 4.9% 4.7% 4.0%
Total 11,174 13,807 13,554 13,169 12,908 12,550 13,649 14,259
Transfused
Autologous N/A N/A 369 566 482 421 367 359
Percentage of total 3.1% 5.0% 4.3% 3.7% 3.0% 2.6%
Total 9934 12,159 12,059 11,307 11,107 11,476 12,389 13,361
Values are expressed as thousands of units, unless otherwise stated. N/A, Not available. Adapted with permission from [3].
Table 2
Erythropoiesis during autologous blood donation
Blood removed (donated) Blood produced
Baseline Requested/donated 
Patients (n) RBCs (ml) units RBCs (ml) RBCs (ml) Expansion (%) Iron therapy Reference
‘Standard phlebotomy’
108 1884 3/2.7 522 351 19% po [6]
22 1936 3/2.8 590 220 11% None [7]
45 1991 3/2.9 621 331 17% po [7]
41 1918 3/2.9 603 315 16% po + iv [7]
‘Aggressive phlebotomy’
30 2075 ≥3/3.0 540 397 19% None [8]
30 2024 ≥3/3.1 558 473 23% po [8]
30 2057 ≥3/2.9 522 436 21% iv [8]
24 2157 6/4.1 683 568 26% po [9,10]
23 2257 6/4.6 757 440 19% po [11]
Values are expressed as means. iv, intravenous; po, oral; RBC, red blood cell. Data from Goodnough and coworkers [5].S51
undergoing these procedures [17] found that 60% under-
went PAD. For non-anemic patients, PAD reduced allogeneic
blood exposure by two thirds as compared with patients who
did not undergo PAD. For anemic (hemoglobin <13 g/dl)
patients, PAD reduced allogeneic blood exposure by only one
third.
For procedures such as total joint replacement surgery,
discard rates of up to 50% of collected units are common
[17]. When autologous blood is collected for procedures that
seldom require transfusion, such as vaginal hysterectomies,
up to 90% of units collected for these procedures are wasted
[16]. The additional costs associated with the collection of
autologous units and the inherent ‘wastage’ of these units,
along with advances in the safety of allogeneic blood, now
render the pre-donation of autologous blood poorly cost-
effective [18]. Cost-effectiveness models serve to illustrate
the potential risks associated with autologous blood dona-
tion; even a very remote risk for death in patients with
ischemic heart disease may entirely negate the benefits of
having  autologous blood available before coronary artery
bypass grafting [19]. Key factors include the estimated postop-
erative lifespan of the patient and the likelihood of transfusion
[20,21]. In a study of autologous blood donation before coro-
nary artery bypass grafting [19], the preoperative donation of 2
units was estimated to have a cost of US$500,000 per quality-
adjusted life year. In comparison, most commonly accepted
medical and surgical interventions have a cost of less than
US$50,000 per quality-adjusted life year. The risk for exposure
to a hepatitis virus or to HIV has declined by at least an order of
magnitude since the calculation of this estimate, and the
current cost-effectiveness would be significantly worse.
Some suggestions to make autologous blood programs less
costly include abbreviating the donor interview for autologous
collection, utilizing only whole blood and discontinuing com-
ponent production, limiting the use of frozen autologous
blood, applying the same transfusion guidelines for autolo-
gous and allogeneic blood, and testing only the first donated
autologous blood unit for infectious disease markers.
Attempts to stratify patients into groups at high and low risk
for transfusion, based on the baseline level of hemoglobin
and on the type of procedure, show some promise. In a study
using a point score system, 80% of patients undergoing total
joint replacement procedures were identified to be at low risk
(<10%) for transfusion, so that autologous blood procure-
ment for these patients would not be recommended [22].
Safety considerations
Autologous blood donation and the transfusion of autologous
blood are each associated with risks. One in 16,783 autolo-
gous donations is associated with an adverse reaction severe
enough to require hospitalization, which is 12 times the risk
associated with community donations by healthy individuals
[23]. Ischemic events have also been reported to occur in
association with autologous blood donation [24]. The transfu-
sion of autologous blood has many of the same complications
as transfusion of allogeneic units, including bacterial contami-
nation, hemolysis due to errors in the administration of units,
and volume overload. Because mortality from allogeneic
blood transfusion is now more likely due to administrative
error [25] than to blood-transmitted infection [3], the risks
associated with banked autologous blood units are similar to
those with banked allogeneic blood units. As summarized
above, some advantages and disadvantages of PAD are
listed in Table 3.
Conclusion
Increased attention to the costs and safety of health care
delivery has caused the relative benefits and costs of both
blood transfusion and conservation to be scrutinized. The
prospective identification of surgical candidates who will
need transfusion and will therefore truly benefit from blood
conservation must be based on factors specific to the patient,
such as the baseline hematocrit and the anticipated blood
loss during surgery. The decision to employ blood-sparing
technology may no longer be based on the safety of the
blood supply, but on evidence that blood conservation is safe





Advantages and disadvantages of autologous blood donation
Advantages Disadvantages
Prevents transfusion-transmitted disease Risk of bacterial contamination or volume overload remains
Prevents red cell alloimmunization Does not eliminate risk of administrative error with ABO incompatibility
Supplements the blood supply More costly than allogeneic blood
Provides compatible blood for patients with alloantibodies Wastage of blood not transfused
Prevents some adverse transfusion reactions Causes perioperative anemia and increased likelihood of transfusion
Data from Goodnough and coworkers [2].S52
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